Verastem to Present at 2011 CEO Biotech Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Verastem, Inc., a biopharmaceutical company focused on discovering and developing novel drugs to treat cancer by targeting cancer stem cells, announced today that the company will be presenting at the 2011 CEO Biotech Conference on Tuesday, June 21 2011 at the Mandarin Oriental, Boston.

Verastem, a privately-funded biotech company, will present on both “The Role of Biotech in Drug Discovery and Development” and “Pharmaceutical R&D.” Verastem was founded and is advised by leading academics with notable track records of translating ground breaking science into significant therapeutic advancements – including Julian Adams, George Daley, Daniel Haber, Roger Tung, Yossi Schlessinger, Phil Sharp and Eric Winer. Verastem utilizes transformative science to develop drugs for untreatable cancers. The management team and board of directors have extensive experience in creating successful organizations and marketed products.

The CEO Biotech Conference, an exclusive networking forum for industry CEOs, offers access to the key decision makers in the life sciences. The conference attracts over 250 of the world's leading pharma and biotech CEOs.

About Verastem, Inc.

Verastem, Inc. is a private biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer.

Verastem was founded by Rich Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric Lander, Robert Weinberg and Christoph Westphal; and is backed by Bessemer Venture Partners, Cardinal Partners, Longwood Founders Fund, and MPM Capital.

www.verastem.com
www.bbbiotechconference.com



CONTACT:

Weber Shandwick
Lacy Roosevelt, 617-520-7052
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.